Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Ingenuity Ink Co-promotion Deal

NEW YORK (GenomeWeb News) – Ingenuity Systems and Affymetrix today announced a deal to co-promote each other's products.

Specifically, the terms of the deal call for the firms to co-promote Ingenuity iReport with Affy's expression microarray products. The combined products, Ingenuity and Affy said, will provide researchers a sample-to-insight continuous workflow "for rapid, confident interpretation of results without the need for bioinformatics experience or support."

Ingenuity iReport is an interactive, web-based report that uses the Ingenuity Knowledge Base of biological and chemical data culled from peer-reviewed literature and databases.

"Bundling together our robust expression microarrays with the iReport platform will provide Affymetrix's customers with a simple and accurate tool to convert data into biologically relevant results," Kevin Cannon, senior vice president of the expression business unit at Affy, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.